全球血紅素病市場 2024-2031

血紅蛋白疾病市場規模、佔有率和趨勢分析報告，按類型（地中海貧血、鐮狀細胞疾病等）、治療（單株抗體藥物、ACE抑制劑、羥基脲等）和配銷通路（醫院藥房、線上提供者和藥局和零售藥局），預測期（2024-2031）

預計在預測期內（2024-2031 年）血紅蛋白病市場將以 7.9% 的複合年成長率成長。血紅蛋白疾病是由血紅蛋白分子 DNA 基因突變引起的。血紅素分子的結構異常會產生有缺陷的紅血球，這是鐮狀細胞疾病的根本原因。此外，亞洲和非洲地區血紅素相關疾病的發生率較高。根據世界衛生組織 (WHO) 的數據，全球 7.0% 的人口受到血紅蛋白疾病的影響。世界衛生組織也估計，有 30,000-40,000 名新生兒攜帶來自父母的嚴重血紅蛋白疾病，這是一種遺傳性疾病。

目錄

第 1 章：報告摘要

• 目前行業分析及成長潛力展望
• 研究方法和工具
• 市場區隔
  • 按細分
  • 按地區

第 2 章：市場概述與見解

• 報告範圍
• 分析師見解和當前市場趨勢
  • 主要市場趨勢
  • 建議
  • 結論

第 3 章：競爭格局

• 主要公司分析
• Novartis AG
  • 概述
  • 財務分析
  • SWOT分析
  • 最近的發展
• Pfizer Inc.
  • 概述
  • 財務分析
  • SWOT分析
  • 最近的發展
• Sangamo Therapeutics
  • 概述
  • 財務分析
  • SWOT分析
  • 最近的發展
• Sanofi SA
  • 概述
  • 財務分析
  • SWOT分析
  • 最近的發展
• 關鍵策略分析

第 4 章：市場細分

• 按類型分類的全球血紅素疾病市場
  • 地中海型貧血
  • 鐮形血球貧血症
  • 其他（血紅素 (Hb) 變異體）
• 按治療分類的全球血紅素疾病市場
  • 單株抗體藥物
  • ACE抑制劑
  • 羥基脲
  • 其他（輸血、鐵螯合療法、骨髓移植）
• 按配銷通路分類的全球血紅素疾病市場
  • 醫院藥房
  • 線上提供者
  • 藥局和零售藥房

第 5 章：區域分析

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 西班牙
  • 法國
  • 歐洲其他地區
• 亞太
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

第 6 章：公司簡介

• Abbott Laboratories
• Alnylam Pharmaceuticals, Inc.
• BIOGEN Inc.
• Bio-Rad Laboratories Inc.
• Bioverativ Inc.
• Bluebird Bio Inc.
• Canthera Discovery Ltd.
• Celgene Corporation
• Danaher Corporation
• Emmaus Medical, Inc.
• Gamida Cell Ltd.
• Global Blood Therapeutics, Inc.
• Merck & Co. Inc.
• Mindray Medical International Ltd.
• Nihon Kohden Corporation
• PerkinElmer, Inc.
• Prolong Pharmaceuticals LLC
• Silence Therapeutics

Hemoglobinopathies Market Size, Share & Trends Analysis Report by Type (Thalassemia, Sickle Cell Disease, and Others), by Therapy (Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, and Others), and by Distribution Channel (Hospital Pharmacy, Online Providers, and Drug Stores and Retail Pharmacy), Forecast Period (2024-2031)

Hemoglobinopathies market is anticipated to grow at a CAGR of 7.9% during the forecast period (2024-2031). Hemoglobinopathies are caused by a mutation in the gene of DNA of hemoglobin molecule. Structural abnormalities in the hemoglobin molecule generate defective red blood cells, which is a root cause of sickle cell disease. Furthermore, the presence of hemoglobin-related diseases is higher in Asia and Africa region. According to the World Health Organization (WHO), 7.0% of the world's population is affected by hemoglobinopathies. WHO also estimated that 30,000-40,000 newborn babies carry severe hemoglobinopathies from their parents as a genetic disorder.

Market Dynamics

Growing Awareness about Hemoglobinopathy

The increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are the driving factors of the market growth. Further, the insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are expected to drive market growth. Also, the increasing number of blood donations in government initiatives is helping to boost market growth. Moreover, many patients with sickle cell disease & thalassemia are also helping to boost the market growth over the forecast period.

Rising Prevalence of Hemoglobin Disorders Drives the Market Growth

Globally, the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high-impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60.0% of the 229 countries affecting over 70.0% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as alpha (a) and beta (B) thalassemia have also gained significant attention in recent years due to the change in the US demographics.

Market Segmentation

Our in-depth analysis of the global hemoglobinopathies market includes the following segments by type, therapy, and distribution channel:

• Based on type, the market is segmented into thalassemia, sickle cell disease, and others.
• Based on therapy, the market is segmented into monoclonal antibody medication, ace inhibitors, hydroxyurea, and others.
• Based on distribution channel, the market is segmented into hospital pharmacies, online providers, and drug stores and retail pharmacies.

Sickle Cell Disease is Projected to Emerge as the Largest Segment

The sickle cell disease segment is expected to hold the largest share of the market. The sickle cell disease diagnosis market has witnessed prominent trends in recent years. One substantial trend is the development and adoption of innovative diagnostic technologies. Advances in genetic testing, including next-generation sequencing and molecular diagnostics, have enabled more accurate and efficient identification of sickle cell disease and its variants. Point-of-care testing (POCT) devices and rapid diagnostic kits have also emerged, allowing for quick and convenient screening in various healthcare settings. For instance, in May 2023, Molbio Diagnostics collaborated with ShanMukha Innovations to design, develop, and commercialize reasonably priced point-of-care diagnostic devices for diagnosing hemoglobinopathy-related diseases.

Monoclonal Antibody Medication Segment to Hold a Considerable Market Share

The monoclonal antibody medication segment holds a considerable market share in the hemoglobinopathy market. It is because of the sufficient medications available for the therapy and because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are like antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.

Regional Outlook

The global hemoglobinopathies market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific to Experience the Rapid Market Growth

Asia-Pacific is anticipated to exhibit the fastest growth rate over the forecast period. The presence of many patients with sickle cell disease and thalassemia is expected to propel market growth in the coming years. Favorable government initiatives to improve the standard of care provided to patients affected with hemoglobinopathies contribute to the region's market growth. For instance, in May 2023, the Union Minister of State for Health and Family Welfare launched the third phase of the Thalassemia Bal Sewa Yojana of the Health Ministry. The government also launched the Thalassemia Bal Sewa Yojana Portal.

North America Holds Major Market Share

North America holds a significant share owing to increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Various organizations spread awareness by conducting different programs. For instance, SCDAA is a national organization in the US that promotes awareness, advocacy, and support for individuals and families affected by sickle cell disease. They provide resources and educational materials and host events to increase understanding and improve the lives of those with the condition. Various initiatives undertaken by research organizations and government bodies to promote research to develop novel therapies for treating hemoglobinopathies are likely to contribute to the market growth in the region.

Market Players Outlook

The major companies serving the global hemoglobinopathies market include Novartis AG, Pfizer Inc., Sangamo Therapeutics, and Sanofi, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in March 2023, Bluebird Bio applied its sickle cell gene therapy, lovo-cel to the FDA for approval. The drug upon approval would compete with CRISPR Therapeutics and Vertex Pharmaceuticals. The therapy is expected to be commercialized by the second half of 2023.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Market Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Novartis AG
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Pfizer Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Sangamo Therapeutics
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Sanofi SA
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Hemoglobinopathies Market by Type
  • 4.1.1. Thalassemia
  • 4.1.2. Sickle Cell Disease
  • 4.1.3. Others (Hemoglobin (Hb) Variants)
• 4.2. Global Hemoglobinopathies Market by Therapy
  • 4.2.1. Monoclonal Antibody Medication
  • 4.2.2. ACE inhibitors
  • 4.2.3. Hydroxyurea
  • 4.2.4. Others (Blood Transfusion, Iron Chelation Therapy, and Bone Marrow Transplant)
• 4.3. Global Hemoglobinopathies Market by Distribution Channel
  • 4.3.1. Hospital Pharmacy
  • 4.3.2. Online Providers
  • 4.3.3. Drug Stores and Retail Pharmacy

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. Abbott Laboratories
• 6.2. Alnylam Pharmaceuticals, Inc.
• 6.3. BIOGEN Inc.
• 6.4. Bio-Rad Laboratories Inc.
• 6.5. Bioverativ Inc.
• 6.6. Bluebird Bio Inc.
• 6.7. Canthera Discovery Ltd.
• 6.8. Celgene Corporation
• 6.9. Danaher Corporation
• 6.10. Emmaus Medical, Inc.
• 6.11. Gamida Cell Ltd.
• 6.12. Global Blood Therapeutics, Inc.
• 6.13. Merck & Co. Inc.
• 6.14. Mindray Medical International Ltd.
• 6.15. Nihon Kohden Corporation
• 6.16. PerkinElmer, Inc.
• 6.17. Prolong Pharmaceuticals LLC
• 6.18. Silence Therapeutics

LIST OF TABLES

• 1. Global Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 2. Global Thalassemia Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 3. Global Sickle Cell Disease Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 4. Global Others Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 5. Global Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 6. Global Monoclonal Antibody Medication For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 7. Global Ace Inhibitors For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 8. Global Hydroxyurea For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 9. Global Others Hemoglobinopathies Therapy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 10. Global Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 11. Global Hemoglobinopathies Via Hospital Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 12. Global Hemoglobinopathies Via Online Providers Market Research And Analysis By Region, 2023-2031 ($ Million)
• 13. Global Hemoglobinopathies Via Drug Stores And Retail Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 14. Global Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 15. North American Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 16. North American Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 17. North American Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 18. North American Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 19. European Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 20. European Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 21. European Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 22. European Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 23. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 24. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 25. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 26. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 27. Rest Of The World Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 28. Rest Of The World Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 29. Rest Of The World Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 30. Rest Of The World Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)

LIST OF FIGURES

• 1. Global Hemoglobinopathies Market Share By Type, 2023 Vs 2031 (%)
• 2. Global Thalassemia Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 3. Global Sickle Cell Disease Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 4. Global Others Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 5. Global Hemoglobinopathies Market Share By Therapy, 2023 Vs 2031 (%)
• 6. Global Monoclonal Antibody Medication For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 7. Global Ace Inhibitors For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)

Global Hydroxyurea For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)

• 8. Global Hemoglobinopathies Market Share By Distribution Channel, 2023 Vs 2031 (%)
• 9. Global Hemoglobinopathies Via Hospital Pharmacy Market Share By Region, 2023 Vs 2031 (%)
• 10. Global Hemoglobinopathies Via Online Providers Market Share By Region, 2023 Vs 2031 (%)
• 11. Global Hemoglobinopathies Via Drug Stores And Retail Pharmacy Market Share By Region, 2023 Vs 2031 (%)
• 12. Global Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 13. US Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 14. Canada Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 15. UK Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 16. France Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 17. Germany Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 18. Italy Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 19. Spain Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 20. Rest Of Europe Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 21. India Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 22. China Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 23. Japan Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 24. South Korea Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 25. Rest Of Asia-Pacific Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 26. Latin America Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 27. Middle East And Africa Hemoglobinopathies Market Size, 2023-2031 ($ Million)